110.86

3.98% 4.24

Pre-market: 113.51 2.65 +2.39%

Sarepta Therapeutics Inc (SRPT)

Overview News Price History Option Chain Financials Why SRPT Down? Discussions Forecast Stock Split

Sarepta Therapeutics Inc stock is traded at $110.86, with a volume of 1.16M. It is up +3.98% in the last 24 hours and down -12.76% over the past month. Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's strategy involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Most of company's product candidates are at an early stage of development.

Previous Close:

$106.62

Open:

$110.46

24h Volume:

1.16M

Relative Volume:

1.36

Market Cap:

$10.51B

Revenue:

$1.50B

Net Income/Loss:

$47.30M

P/E Ratio:

-14.16

EPS:

-7.83

Net Cash Flow:

$-527.92M

1W Performance:

-1.44%

1M Performance:

-12.76%

6M Performance:

-15.26%

1Y Performance:

+33.47%

1-Day Range:

$108.72

$111.38

1-Week Range:

$102.16

$112.58

52-Week Range:

$78.67

$173.25

Sarepta Therapeutics Inc Stock (SRPT) Company Profile

Name

Sarepta Therapeutics Inc

Sector

Healthcare (1193)

Industry

Biotechnology (683)

Phone

617-274-4000

Address

215 FIRST STREET, CAMBRIDGE, MA

Employee

1,314

Twitter

@sarepta

Next Earnings Date

2024-11-06

Latest SEC Filings

SRPT's Discussions on Twitter

Compare SRPT with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
SRPT	110.86	10.51B	1.50B	47.30M	-527.92M	-7.83
VRTX	451.23	115.74B	10.63B	-479.80M	-1.35B	13.33
REGN	743.35	81.65B	13.85B	4.65B	3.32B	35.06
ARGX	591.82	34.86B	1.86B	-40.29M	-1.28B	-4.16
ALNY	248.79	32.09B	2.09B	-332.26M	16.06M	-4.14
BNTX	102.14	24.49B	3.30B	-501.07M	1.03B	11.54

Sarepta Therapeutics Inc Stock (SRPT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-31-24	Initiated	BMO Capital Markets	Outperform
Dec-13-23	Resumed	Citigroup	Buy
Dec-12-23	Initiated	Deutsche Bank	Buy
Nov-21-23	Initiated	Wedbush	Outperform
Oct-31-23	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Oct-31-23	Downgrade	Oppenheimer	Outperform → Perform
Jun-23-23	Downgrade	Evercore ISI	Outperform → In-line
Apr-26-23	Initiated	SMBC Nikko	Outperform
Apr-04-23	Initiated	Citigroup	Buy
Mar-01-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Dec-22-22	Reiterated	BTIG Research	Buy
Dec-16-22	Upgrade	UBS	Neutral → Buy
Apr-04-22	Resumed	Cantor Fitzgerald	Overweight
Jan-05-22	Reiterated	Needham	Buy
Dec-09-21	Upgrade	Oppenheimer	Perform → Outperform
Nov-05-21	Upgrade	JP Morgan	Neutral → Overweight
Sep-15-21	Upgrade	Guggenheim	Neutral → Buy
Aug-05-21	Upgrade	JP Morgan	Underweight → Neutral
Jun-15-21	Initiated	BTIG Research	Buy
Apr-26-21	Resumed	Credit Suisse	Neutral
Jan-12-21	Downgrade	Citigroup	Buy → Neutral
Jan-11-21	Downgrade	UBS	Buy → Neutral
Jan-08-21	Downgrade	JP Morgan	Overweight → Underweight
Jan-08-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Jan-08-21	Downgrade	Raymond James	Outperform → Mkt Perform
Nov-11-20	Initiated	Berenberg	Hold
Oct-28-20	Initiated	UBS	Buy
Aug-25-20	Initiated	Raymond James	Outperform
Aug-20-20	Downgrade	Credit Suisse	Outperform → Neutral
Mar-31-20	Initiated	Mizuho	Buy
Nov-01-19	Initiated	Guggenheim	Buy
Aug-21-19	Reiterated	Needham	Buy
Jul-09-19	Reiterated	Morgan Stanley	Overweight
Jul-01-19	Reiterated	RBC Capital Mkts	Outperform
Apr-12-19	Initiated	Evercore ISI	Outperform
Mar-11-19	Reiterated	Credit Suisse	Outperform
Oct-12-18	Initiated	Bernstein	Outperform
Oct-01-18	Initiated	Cantor Fitzgerald	Overweight
Sep-26-18	Reiterated	RBC Capital Mkts	Outperform
Sep-14-18	Resumed	BofA/Merrill	Buy
Sep-06-18	Initiated	Credit Suisse	Outperform
Aug-01-18	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Jun-21-18	Reiterated	Robert W. Baird	Outperform
Jun-20-18	Reiterated	Needham	Buy
Jun-19-18	Reiterated	H.C. Wainwright	Buy

View All

Sarepta Therapeutics Inc Stock (SRPT) Latest News

Nov 20, 2024

Braun Stacey Associates Inc. Grows Stock Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat

Nov 18, 2024

Thrivent Financial for Lutherans Trims Stock Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat

Nov 18, 2024

FDA endorses speedy approval path for Regenxbio Duchenne gene therapy - Yahoo Finance

Nov 18, 2024

Nov 17, 2024

Cantor Fitzgerald Upgrades Sarepta Therapeutics (SRPT) - MSN

Nov 17, 2024

Aigen Investment Management LP Lowers Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat

Nov 17, 2024

Nov 16, 2024

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Purchased by Mizuho Markets Americas LLC - MarketBeat

Nov 16, 2024

Nov 15, 2024